Patent classifications
A61L2300/418
Autologous bone graft substitute composition
An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects, a method of preparation thereof, and a method of inducing or promoting bone growth by treatment of a bone with an autologous bone graft substitute composition. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof; and a compression resistant matrix selected from the group consisting of a bone autograft, bone allograft, hydroxyapatite, tri-calcium phosphate, and combinations thereof. The autologous blood forms a coagulum gel comprising a fibrin-meshwork reinforced with the compression resistant matrix and containing the osteogenic bone morphogenetic protein which is released over a sustained period.
Composition for hemostasis and container comprising same
The present invention relates to a composition for hemostasis which contains collagen, stabilizer, and thrombin, and a container including the same. The present invention is applicable to a bleeding patient requiring emergency treatment with a simple method of use. There is no toxicity and no problem of blood infection. A biodegradation rate is fast. In this regard, the present invention achieves an excellent hemostatic effect. Therefore, the composition for hemostasis is useful as a hemostat.
System and method for treating nasal bleeding
A blood coagulant assembly includes a blood coagulant device adapted to be insertable into a nostril of a patient to stop a nose bleed. The blood coagulant device is mounted within a blood coagulant device container which has a top container section and a lower container section secured to each other in a releasable manner. The blood coagulant device is mounted in a fixed position within the blood coagulant device container prior to its removal from the blood coagulant container. The blood coagulant device has a rigid handle configured with a handle lower section and a handle upper section contoured with a channel passing through both the lower and upper handle sections. A blood coagulant mechanism is secured to an outer surface of the handle upper section and a to a ledge section of the handle member which extends radially at a joint location of the handle's lower and upper sections.
HEMOSTATIC MATERIAL COMPOSITION
The hemostatic material composition contains a polysaccharide having a reactive group that reacts with a protein to form a crosslinking structure and contains a hydrophobic solvent.
EXTRACELLULAR MATRIX SHEET STRUCTURES
An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.
FIBRINOGEN COMPRISING FORMULATION AND USES THEREOF
The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.
TRANEXAMIC ACID SPRAY FOR KNEE ARTHROPLASTY
The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.
Layer of material for a surgical end effector
A staple cartridge comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises an uncompressed height, a compressed height, an outer encasement, and tubular structures aligned along the longitudinal axis. The tubular structures are configured to collapse when pressure is applied to the tissue thickness compensator by tissue during the firing motion.
PREPARATION METHOD FOR AND USE METHOD OF COLLAGEN MICROFIBER HEMOSTATIC MATERIAL
Disclosed in the present invention are a preparation method for and a use method of a collagen microfiber hemostatic material. Collagen microfibers are obtained by performing high-speed shearing on a solid collagen material, after the collagen microfibers are dispersed in an aqueous phase, a procoagulant active ingredient modifies the surfaces of the collagen microfibers by means of linking molecules; and a collagen microfiber hemostatic material is obtained by performing high-speed shearing again after freeze drying. The collagen microfiber material can be prepared simply and efficiently by means of high-speed shearing; the biological activity of the collagen material is maintained as much as possible; and the microfibers have a length range of 10-1000 μm and high dispersibility, thus facilitating spray processing. The procoagulant active ingredient can be efficiently and quantitatively loaded on the surfaces of the collagen microfibers by means of the linking molecules to enhance the hemostatic effect of the collagen microfibers. The collagen microfiber hemostatic material prepared in the present invention can be used for hemostasis of a bleeding wound by means of spraying application, thereby achieving the effect of non-contact fixed-point hemostasis.
NANOFIBER STRUCTURES AND METHODS OF USE THEREOF
Expanded, nanofiber structures are provided as well as methods of use thereof and methods of making.